Welcome to our dedicated page for ALBEMARLE SEC filings (Ticker: ALB), a comprehensive resource for investors and traders seeking official regulatory documents including 10-K annual reports, 10-Q quarterly earnings, 8-K material events, and insider trading forms.
Albemarle Corporation filings document operating results, material events, governance matters, shareholder voting items, and capital-structure disclosures for a public specialty chemicals and critical materials company. Form 8-K reports cover quarterly financial results, credit agreement amendments, debt-related actions, board appointments, officer transitions, and completed portfolio transactions.
Proxy materials describe director elections, committee governance, executive compensation, shareholder proposals, and voting procedures. Albemarle's filing record also documents the completed disposition of a controlling stake in Ketjen, retained ownership interests, integration of Performance Catalyst Solutions, and financing arrangements tied to the company's global lithium, bromine and specialty product businesses.
ALBEMARLE CORP director Laurie Brlas reported equity awards of common stock as part of non-employee director compensation. On July 1, 2026, Brlas received two acquisitions of common stock valued at $0.00 per share, reflecting stock-based compensation rather than open-market purchases.
The filing shows an award of 1,250 shares of common stock as an annual installment of non-employee director stock compensation under the 2023 Stock Compensation and Deferral Election Plan for Non-Employee Directors of Albemarle Corporation, scheduled to vest on July 1, 2027. It also shows 36 shares issued for dividends accrued on a prior award granted on July 1, 2025 that vested in full on July 1, 2026, which the company elected to settle in stock under the same plan.
After these awards, Brlas holds 7,289 shares of Albemarle common stock directly and 6,900 shares indirectly through a spouse, according to the filing.
ALBEMARLE CORP director Alejandro Daniel Wolff acquired additional equity-based compensation and dividend-related holdings in the company. He received 33 shares of common stock at no cost through an automatic dividend reinvestment program and now directly holds 13,044 common shares.
He also was granted 1,250 Phantom Stock units, which convert 1-for-1 into common stock and are payable as shares under the 2023 Directors Plan, bringing his Phantom Stock balance to 7,590 units. These Phantom Stock amounts include dividend equivalent rights and represent an annual non-employee director stock installment scheduled to vest on July 1, 2027.
Albemarle Corporation director Mark R. Widmar received an equity-based compensation award. He was granted 1,250 Phantom Stock units that convert one-for-one into Albemarle common stock. Following this grant, he holds 1,576 Phantom Stock units in his deferred stock account.
The units are an annual non-employee director stock compensation award under Albemarle’s 2023 Stock Compensation and Deferral Election Plan for Non-Employee Directors and are payable in shares of common stock upon distribution events selected under the plan. The award is scheduled to vest on July 1, 2027 and has no expiration date.
Albemarle Corporation director Gerald A. Steiner reported stock-based compensation awards rather than open-market trades. He acquired 36 shares of common stock as an annual non-employee director stock compensation installment under the 2023 Directors Plan, scheduled to vest on July 1, 2027. He also received 1,250 additional shares that represent dividends accrued on a prior stock award granted on July 1, 2025 and vested on July 1, 2026, which the company elected to settle in shares. These transactions reflect equity compensation grants and dividend equivalents, not cash purchases or sales.
ALBEMARLE CORP reported a routine equity compensation award for non-employee director Holly Van Deursen. She received 1,250 Phantom Stock units, which convert 1-for-1 into common stock. These units represent annual director stock compensation under Albemarle’s 2023 Directors Plan and are scheduled to vest on July 1, 2027.
The Phantom Stock will be paid in shares of common stock upon events she has established under the plan. Following this award, Van Deursen now holds 10,028 Phantom Stock units in her deferred stock account. This is a grant/award acquisition, not an open-market purchase or sale.
ALBEMARLE CORP director Diarmuid B. O’Connell reported stock-based compensation awards rather than open-market trades. On July 1, 2026, he acquired a total of 1,286 shares of common stock at no cash cost, recorded as grants or awards.
Footnotes explain that 36 shares are an annual installment of non-employee director stock compensation under the 2023 Stock Compensation and Deferral Election Plan for Non-Employee Directors, scheduled to vest on July 1, 2027. Additional shares represent dividends accrued on a prior award granted on July 1, 2025 that vested on July 1, 2026, which the company settled in stock issued under the same plan.
The filing also notes that the director’s holdings were adjusted to reflect a transfer of 893 shares of common stock pursuant to an agreement of separation of assets, indicating a reallocation of previously held shares rather than a market sale.
Albemarle Corporation announced a routine leadership change in its finance function. Former Chief Accounting Officer Donald J. LaBauve Jr. retired on June 1, 2026. Executive Vice President and Chief Financial Officer Neal R. Sheorey will serve as interim Principal Accounting Officer effective June 2, 2026, until the board appoints a permanent replacement.
The company states that Mr. Sheorey will not receive any new compensatory arrangements for this interim role. Albemarle also notes there are no family relationships between him and other directors or executive officers and no related-party transactions requiring disclosure under Item 404(a) of Regulation S-K.
Albemarle Corporation Chairman & CEO J. Kent Masters sold a total of 16,393 shares of Common Stock in open-market transactions on May 15, 2026. The sales were executed in three tranches: 700 shares at a weighted average price of $184.52, 11,867 shares at $183.87, and 3,826 shares at $183.12. Footnotes state the trades were carried out in multiple transactions within price ranges between $182.415 and $184.54 for diversification and tax planning purposes. The disclosure also notes that the reporting person retains significant Albemarle holdings in excess of required stock ownership guidelines.
Jerry Kent Masters Jr. reported a sale of 11,783 shares of Common Stock on 03/10/2026 under a Rule 144 filing. The filing lists multiple Restricted Stock Units previously acquired as compensation on 02/18/2022 (1,673), 04/19/2023 (771), 05/05/2023 (2,363), 12/31/2023 (4,881 and 1,597) and 02/26/2026 (5,108).
Albemarle Corp. Schedule 13G/A amendment shows Capital World Investors reports beneficial ownership of 11,279,425 shares, equal to 9.5% of the 119,078,534 shares believed to be outstanding. The filing states that the position includes 3,124,652 Convertible Preferred Stocks that represent 1,427,966 common shares.